Kontrol Technologies Corp (OTCQB:KNRLF, NEO:KNR)., a leader in smart building technology, has shipped its BioCloud technology to a new customer in Hong Kong.
The customer operates as an integrated national air quality and smart building solutions provider.
In addition, the company said a testing partner has completed its first BioCloud technology purchase.
READ: Kontrol Technologies says its Global subsidiary is awarded $9.7M HVAC and automation project for Toronto high-rise building
"As organic, internal innovation for early viral detection and continuous monitoring of air quality, we are pleased to continue to grow the BioCloud technology," said Paul Ghezzi, CEO of Kontrol Technologies, in a statement.
Meanwhile, Kontrol said it received an order for a trial of the BioCloud technology for use in classroom applications in the US from an integrated air quality solutions company.
The pilot and study are expected to run for multiple months, with inception anticipated in the early part of the second quarter of 2022.
Kontrol stressed that it is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
The BioCloud technology is a real-time analyzer designed to detect airborne viruses and pathogens. BioCloud is an air quality technology and not a medical device. BioCloud has been designed to operate as a safe space technology by sampling the air quality continuously. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and a silent notification system is created. It can be applied to any space where individuals gather.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham